FREQUENTLY ASKED / PT-141
PT-141 questions, answered straight and cited.
Direct answers to the most common questions about PT-141 (bremelanotide) — the approved use, the mechanism, the male research, and dosage — each quantitative claim tied to a study.
What is PT-141 used for?
Bremelanotide (PT-141) is FDA-approved for one use only: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. Every other use — in men, for erectile dysfunction, in postmenopausal women, or for sexual performance — is off-label and not supported by the approval [6].
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1][6]. Bremelanotide is the FDA-approved injectable drug; material sold as "PT-141 research chemical" is laboratory material only, not the finished drug product [11].
What is PT-141 peptide?
A cyclic heptapeptide — seven amino acids joined in a ring — that is a synthetic analogue of alpha-melanocyte-stimulating hormone [6]. Its ring structure makes it more stable than linear peptides, and it acts on melanocortin receptors in the brain rather than on blood vessels [1][6].
What does the PT-141 peptide do?
It activates central melanocortin receptors (chiefly MC4R, with MC3R) in hypothalamic and limbic circuits linked to sexual desire and arousal [1]. It is thought to engage dopaminergic pathways tied to appetitive sexual behavior, rather than acting on blood flow [1][2].
Is PT-141 the same as bremelanotide?
Yes. Bremelanotide is the international nonproprietary name (INN) for the compound, and PT-141 is its long-standing research designation [6]. The approved injectable drug product is bremelanotide; "PT-141" is the name commonly used in the research-chemical context [6][11].
What is bremelanotide?
Bremelanotide is a melanocortin MC3R/MC4R receptor agonist approved by the FDA in June 2019 (NDA 210557) for HSDD in premenopausal women, given as a 1.75 mg subcutaneous injection as needed [6]. It is the approved-drug identity of PT-141 [6].
How does PT-141 work?
By stimulating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, PT-141 is thought to engage dopaminergic pathways that govern sexual desire and arousal [1][2]. This is a central mechanism, distinct from the vascular action of PDE-5 inhibitors [1].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 activates central melanocortin receptors (chiefly MC4R) in the hypothalamus and limbic circuits that govern sexual motivation [1]. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, it works on the neural circuitry of desire rather than directly on blood flow [1].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary activity at MC3R [1]. These are the central-nervous-system melanocortin subtypes; activation of MC1R in the periphery explains the hyperpigmentation reported with repeated dosing [6][11].
What is a melanocortin receptor agonist?
A molecule that activates melanocortin receptors — a family of five G-protein-coupled receptors (MC1R-MC5R) that respond to peptides like alpha-MSH [1]. PT-141 is an agonist at the central MC3R and MC4R subtypes [1].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on penile vascular smooth muscle to improve erectile blood flow. PT-141 acts centrally as an MC3R/MC4R agonist on brain circuits of sexual desire [1] — a different mechanism, which is why early research explored combining the two [14].
Does PT-141 increase testosterone?
No. A common misconception is that PT-141 raises testosterone or acts through the hormonal HPG axis [11]. It acts on central melanocortin receptors that modulate sexual desire directly; it is neither a hormone nor a PDE-5 inhibitor [1][11].
What does PT-141 do for men?
In early-phase research, PT-141 produced dose-dependent erectile activity in men with ED via a central mechanism [1]. This use is off-label and investigational only — PT-141 is not approved for men — and a Phase 2 combination study with a PDE-5 inhibitor began in 2024 [6][14].
Is PT-141 approved for men?
No. Bremelanotide's approval covers only premenopausal women with HSDD [6]. There is early-phase erectile-response data in men, but male use remains off-label and investigational, and no male indication has been approved [1][6].
Does PT-141 nasal spray work?
The intranasal formulation was the original route in early men's-ED research: a statistically significant erectile response versus placebo appeared above 7 mg, with onset around 30 minutes [7]. Intranasal development was later discontinued for pharmacokinetic variability and the program moved to subcutaneous injection [7].
Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?
There is no approved head-to-head answer. PDE-5 inhibitors are the established, approved ED therapy; PT-141's male-ED evidence is early-phase [9]. Because the two act by different mechanisms, current development is studying them in combination for PDE-5-inhibitor non-responders rather than as a replacement [14].
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the two mechanisms are complementary: PT-141 acts centrally on desire while PDE-5 inhibitors act peripherally on blood flow [1]. In June 2024 the developer announced a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for men who do not respond to PDE-5-inhibitor monotherapy [14].
What is the PT-141 dosage?
The approved label specifies bremelanotide 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than 8 per month [6]. This is reported strictly as the label finding, not as a protocol for any reader.
How much PT-141 should I take?
This site does not recommend a dose for any individual. The only doses reported are those studied in trials or specified on the approved label (1.75 mg SC as needed for premenopausal-women HSDD) [6]; deciding whether and how a drug applies to a person is a clinician's role.
How much PT-141 to inject?
The approved injectable dose is 1.75 mg subcutaneous per administration [6]. Phase 2 dose-finding in women evaluated 0.75, 1.25, and 1.75 mg [11]. These are research and label findings, not dosing instructions.
What is the PT-141 dosage for women?
For the approved HSDD indication in premenopausal women, the label dose is 1.75 mg subcutaneously as needed (maximum one dose per 24 hours, eight per month) [6]. It was selected from Phase 2 dose-finding (0.75 / 1.25 / 1.75 mg) [11].
How do you reconstitute PT-141?
The approved bremelanotide product is a ready-to-use prefilled subcutaneous autoinjector, not a powder a patient reconstitutes [6]. Reconstitution questions arise around the unapproved "research chemical" lyophilized form, which is laboratory material only [11]; this site describes the literature and label, not preparation steps.